Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02306161 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 650 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Completion pushed from Sep 17, 2026 to Sep 16, 2027 Site details revised at 100 of 314 sites Show 1 more changeShow less
    • Site details revised at 100 of 314 sites
  2. Re-verified, no change to tracked fieldsv649
  3. Study sites revised (314)v648 See this version in full on ClinicalTrials.gov ↗
  4. Study sites revised (314)v647 See this version in full on ClinicalTrials.gov ↗
  5. Study sites: 315 to 314v646
Show 45 earlier versionsHide 45 earlier versions
  1. Re-verified, no change to tracked fieldsv645
  2. Study sites revised (315)v644 See this version in full on ClinicalTrials.gov ↗
  3. Study sites revised (315)v643 See this version in full on ClinicalTrials.gov ↗
  4. 26 versions Re-verified since Mar 4, 2026, no change to tracked fieldsv617-v642
  5. Study sites revised (315)v616 See this version in full on ClinicalTrials.gov ↗
  6. Study sites revised (315)v615 See this version in full on ClinicalTrials.gov ↗
  7. Completion date: Sep 19, 2025 to Sep 17, 2026v614
  8. Study sites revised (315)v613 See this version in full on ClinicalTrials.gov ↗
  9. Re-verified, no change to tracked fieldsv612
  10. Study sites revised (315)v611 See this version in full on ClinicalTrials.gov ↗
  11. Study sites revised (315)v610 See this version in full on ClinicalTrials.gov ↗
  12. Study sites revised (315)v609 See this version in full on ClinicalTrials.gov ↗
  13. Study sites revised (315)v608 See this version in full on ClinicalTrials.gov ↗
  14. Study sites revised (315)v607 See this version in full on ClinicalTrials.gov ↗
  15. Study sites revised (315)v606 See this version in full on ClinicalTrials.gov ↗
  16. Re-verified, no change to tracked fieldsv605
  17. Study sites revised (315)v604 See this version in full on ClinicalTrials.gov ↗
  18. Study sites revised (315)v603 See this version in full on ClinicalTrials.gov ↗
  19. Study sites: 316 to 315v602
  20. Study sites: 317 to 316v601
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Treatment with drugs that block the IGF-1R pathway, such as ganitumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether adding ganitumab to combination chemotherapy is more effective in treating patients with newly diagnosed metastatic Ewing sarcoma.
Trial Details
NCT Number NCT02306161
Lead Sponsor National Cancer Institute (NCI)
Conditions Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow, Metastatic Malignant Neoplasm in the Lung, Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Enrollment 312 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov